イリノイ州における自己免疫疾患の臨床試験
イリノイ州内の拠点で、自己免疫疾患に関する14件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Willow Rheumatology Wellness, Willowbrook
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07621809A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
被験者募集中第2相
16歳〜70歳 · 全性別 · 2026/09/17更新 · NCT07328581RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
被験者募集中第2/3相
6歳〜75歳 · 全性別 · 2026/09/17更新 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Chicago, Department of Medicine: Rheumatology, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07103746A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/10更新 · NCT07085104RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/08/26更新 · NCT06121297A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
- University of Illinois Hospital & Health Sciences System, Chicago
被験者募集中第1/2相
35歳〜70歳 · 全性別 · 2026/08/21更新 · NCT06575426RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
被験者募集中第2/3相
18歳〜75歳 · 全性別 · 2026/08/17更新 · NCT06328777RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/08/13更新 · NCT06359041Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1054, Schaumburg
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/07/30更新 · NCT07039916A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- Northwestern University, Chicago
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/06/30更新 · NCT06201416A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Northwestern University, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/29更新 · NCT04422912The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
- University of Chicago Medical Center, Chicago
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2026/03/04更新 · NCT01280825ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。